REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for aggressive lymphoma: drug combo aims to unmask cancer cells
Disease control OngoingThis study tests a combination of two drugs (TTI-622 and pembrolizumab) in about 10 adults with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. The drugs work by helping the immune system recognize and attack cancer cells. The goal is to find …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
Experimental combo aims to supercharge immune cells against Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial tests whether adding an experimental drug (NKTR-255) to standard CAR-T cell therapy can improve outcomes for adults with large B-cell lymphoma that has returned or not responded to treatment. About 27 participants will receive the combination to see if it i…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:10 UTC